Tumor response information was obtained for all participants who received at least 2 cycles
of study drug, underwent requisite baseline and on-treatment disease assessments and had at
least one post-treatment assessment. Tumor response assessment in evaluable participants was
done according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria.